Beth Kao
Research Subjects
Research Interests
Beth Kao has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Allysonne Smith1 shared publication
- Andrea Linder1 shared publication
- Chad S. Weldy
Stanford University
1 shared publication - Colleen Bonnett
Colleen Bonnett is a cardiac vascular certified nurse, currently the arrhythmia coordinator in the cardiology clinic at Stanford Health Care, Stanford, California
1 shared publication - Cynthia Lamendola1 shared publication
- Daniel Seung Kim
Stanford University
1 shared publication
Latest Publications
- Open Access
- 27 November 2023
- Published by MDPI AG in Preprints.org
One-Year Real-World Experience with Mavacamten and its Physiologic Effects on Obstructive Hypertrophic Cardiomyopathy
We describe real-world use of mavacamten in 50 patients with oHCM. Consistent with EXPLORER-HCM and VALOR-HCM, we report significant improvement in wall thickness, mitral regurgitation, left ventricular outflow tract obstruction and NYHA class. Moreover, in our center’s experience, neither arrhythmia burden, nor contractility have worsened in the vast majority of patients: We note a clinically insignificant mean decrease in left ventricular ejection fraction (LVEF), with only two patients requiring temporary mavacamten discontinuance for LVEF < 50%. Adverse events were rare, unrelated to mavacamten itself, and seen solely in patients with disease too advanced to have been represented in clinical trials. Our multidisciplinary pathway enabled us to provide a large number of patients with a novel closely-monitored therapeutic within just a few months of commercial availability. These data lead us to conclude that mavacamten, as a first-in-class cardiac myosin inhibitor, is safe and efficacious in real-world settings.
- 27 November 2023
- Published by MDPI AG in Preprints.org
Open AccessOne-Year Real-World Experience with Mavacamten and its Physiologic Effects on Obstructive Hypertrophic Cardiomyopathy
We describe real-world use of mavacamten in 50 patients with oHCM. Consistent with EXPLORER-HCM and VALOR-HCM, we report significant improvement in wall thickness, mitral regurgitation, left ventricular outflow tract obstruction and NYHA class. Moreover, in our center’s experience, neither arrhythmia burden, nor contractility have worsened in the vast majority of patients: We note a clinically insignificant mean decrease in left ventricular ejection fraction (LVEF), with only two patients requiring temporary mavacamten discontinuance for LVEF < 50%. Adverse events were rare, unrelated to mavacamten itself, and seen solely in patients with disease too advanced to have been represented in clinical trials. Our multidisciplinary pathway enabled us to provide a large number of patients with a novel closely-monitored therapeutic within just a few months of commercial availability. These data lead us to conclude that mavacamten, as a first-in-class cardiac myosin inhibitor, is safe and efficacious in real-world settings.